Radiotherapy company CIVCO Radiotherapy revealed on Monday the receipt of US FDA 510k clearance and EU CE mark for the Solstice SRS Immobilization System with variable pitch capability and positioning flexibility in aid of patients and doctors in radiotherapy clinics.
The company added that the Solstice SRS Immobilization System will be launched in the market following its display at the American Society for Radiation Oncology (ASTRO) Meeting from 21-24 October 2018 in San Antonio, Texas.
According to the company, the Solstice SRS Immobilization System creates a highly customisable and comfortable head and neck immobilisation system for precise treatment to improve patient outcomes. The system is comprised of a carbon fibre head support, customisable cushion and dedicated thermoplastic mask designed for secure and simple attachment.
In addition, the company's patient-centric solutions include advanced patient immobilisation and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML